Protease-inhibitor boosting in the treatment-experienced patient.
暂无分享,去创建一个
[1] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[2] A. Hsu,et al. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.
[3] R Rode,et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.
[4] J. Gerber. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] F. Hecht,et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.
[6] S. Penzak,et al. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. , 2000, Scandinavian journal of infectious diseases.
[7] R. Manfredi,et al. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. , 2001, The Journal of infection.
[8] A. Hsu,et al. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. , 2001, British journal of clinical pharmacology.
[9] G. Moyle. Use of HIV protease inhibitors as pharmacoenhancers. , 2001, The AIDS reader.
[10] Dale J. Kempf,et al. Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia , 2002, Antimicrobial Agents and Chemotherapy.
[11] P. Sax,et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. , 2002, The Journal of infectious diseases.
[12] R. Zeldin,et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen. , 2002, Journal of acquired immune deficiency syndromes.
[13] V. Soriano,et al. Salvage Treatment with Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients Failing All Current Antiretroviral Drug Families , 2002, HIV clinical trials.
[14] Joel E Gallant,et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] K. Squires,et al. Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects , 2003, Journal of acquired immune deficiency syndromes.
[16] Michael Giordano,et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results , 2003, AIDS.
[17] S. Becker. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy , 2003, Expert opinion on investigational drugs.
[18] D. Haas,et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial , 2003, AIDS.
[19] G. Plosker,et al. Saquinavir: a review of its use in boosted regimens for treating HIV infection. , 2003, Drugs.
[20] C. Cooper,et al. A review of low-dose ritonavir in protease inhibitor combination therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] F. Gutiérrez,et al. Lopinavir Plasma Concentrations and Changes in Lipid Levels During Salvage Therapy with Lopinavir/Ritonavir‐Containing Regimens , 2003, Journal of acquired immune deficiency syndromes.
[22] Z. Fox,et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. , 2003, The Journal of infectious diseases.
[23] A. Hsu,et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.